Abstracts tagged "Cardiovascular"

Abstract Number: 0729 • ACR Convergence 2025
ANCA-associated vasculitis – does the type matter?
Tamanna Vinodkumar Mohta¹ and Umeh Chukwuemeka², ¹Hemet Global Medical Center, Irvine, CA, ²Hemet Global Medical Center, Hemet
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a heterogeneous group of rare autoimmune disorders that cause inflammation of blood vessels with various manifestations. Our study…
Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Eleana Bolla¹, Anne Grete Semb², Michelle Petri³, Petros Sfikakis⁴, Bahar Artim Esen⁵, Gabriela Hernandez-Molina⁶, Eric Hachulla⁷, Haner Direskeneli⁸, George Karpouzas⁹, Marta Mosca¹⁰, Mohit Goyal¹¹, Nathalie Costedoat-Chalumeau¹², Angela Tincani¹³, Ayten Yazici¹⁴, Karoline Lerang¹⁵, Anne Troldborg¹⁶, Sofia Ajeganova¹⁷, Tatiana Popkova¹⁸, Elisabet Svenungsson¹⁹, Nikos Pantazis²⁰ and Maria Tektonidou²¹, ¹Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece, ²Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁵Istanbul University, Istanbul, Istanbul, Turkey, ⁶Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ⁷University of Lille, LILLE, France, ⁸Marmara University, ISTANBUL, Turkey, ⁹Harbor-UCLA Medical Center, Torrance, CA, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹CARE Pain & Arthritis Centre, Udaipur, Rajasthan, India, ¹²Inserm DR Paris ⁵, Paris, France, ¹³ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey, ¹⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁶Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, ¹⁸V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ¹⁹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²⁰Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ²¹National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…
Abstract Number: 2651 • ACR Convergence 2025
Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
Laura Ross¹, Andrew Burns², Andre La Gerche³, Dylan Hansen⁴, Gerry Coghlan⁵, Wendy Stevens⁶, David Prior⁷, Alan Pham⁸, Penelope McKelvie⁴, Chiara Bellocchi⁹, Yolanda Braun Moscovici¹⁰, Cosimo Bruni¹¹, Patricia E. Carreira¹², Tracy Frech¹³, Sabrina Hoa¹⁴, Marie Hudson¹⁵, Vivien Hsu¹⁶, Marco Matucci-Cerinic¹⁷, Benjamin Medina Fonseca¹⁸, Andrea Low¹⁹, Sue-Ann Ng¹⁹, Tatiana Rodriguez-Reyna²⁰, Joanne Sahhar²¹, Mohamed Talaat²², Susanna Proudman²³, Alessandra Vacca²⁴, Murray Baron²⁵ and Mandana Nikpour²⁶, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Hospital Melbourne, Fitzroy, Australia, ³St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁵Royal Free Hospital, London, United Kingdom, ⁶St Vincent's Hospital Melbourne & University of Melbourne, Fitzroy, Australia, ⁷University of Melbourne, Parkville, Australia, ⁸Alfred Hospital, Melbourne, Australia, ⁹University of Milan, Milan, Italy, ¹⁰Rambam Heath Care Campus, Haifa, Israel, ¹¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹³Vanderbilt University Medical Center, Nashville, TN, ¹⁴University of Montreal, Brossard, QC, Canada, ¹⁵McGill University, Montréal, QC, Canada, ¹⁶Rutgers- RWJ Medical School, South Plainfield, NJ, ¹⁷University San Raffaele Milano, Milano, Milan, Italy, ¹⁸Universidad Nacional Autonoma de Mexico, Monterry, Mexico, ¹⁹Singapore General Hospital, Singapore, Singapore, ²⁰Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²¹Monash Health, Melbourne, Victoria, Australia, ²²Augusta Health, Charlottesville, VA, ²³Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ²⁴University and AOU of Cagliari, Monserrato, Italy, ²⁵McGill University, Montreal, Canada, ²⁶University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: Systemic sclerosis (SSc) heart involvement (SHI) is a serious disease manifestation associated with high mortality. This study presents newly developed classification criteria to enable…
Abstract Number: 2325 • ACR Convergence 2025
Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Natalia Guajardo-Jauregui¹, Iris J. Colunga-Pedraza², Dionicio A. Galarza-Delgado², Jose R Azpiri-Lopez³, Jesus Alberto Cardenas-de la Garza⁴, Diana E. Flores-Alvarado⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated condition associated with an increased risk of cardiovascular (CV) events due to disease-specific characteristics. Galectin-3 (Gal-3) is a…
Abstract Number: 1851 • ACR Convergence 2025
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Chary López pedrera¹, Laurel Woodridge², Sagrario Corrales³, Juan Rafael Muñoz-Castañeda⁴, Ana Isabel Torralbo⁴, Anisur Rahman⁵, Filipa Farinha², Rafaela Ortega-Castro⁶, Pedro Seguí-Azpilcueta⁷, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Christian Merlo-Ruiz⁸, Desiree Ruiz-Vilchez⁹, M Carmen Abalos-Aguilera⁸, Pilar Font¹⁰, Nuria Barbarroja¹¹, Marta Alarcon-Riquelme¹², Alejandro Escudero Contreras¹³, MARIA ANGELES AGUIRRE ZAMORANO³, Carlos Pérez Sánchez¹⁴, Elizabeth C Jury⁵ and Tomás Cerdó³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC/Hospital Reina Sofía/University of Córdoba, Córdoba, Spain, ⁵University College London, London, United Kingdom, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹²Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…
Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Aretha On¹, Xiwei Yang¹, Shae Chambers², Hammad Ali³, Touraj Khosravi-Hafshejani³, Lais Lopes Almeida Gomes², Rui Feng⁴, Kevin Jon Williams⁵ and Victoria Werth⁶, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA, Philadelphia, PA, ⁶University of Pennsylvania, Wynnewood, PA
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…
Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Hanna Lindberg¹, Klytaimnistra Voudouri¹, Lars Lindhagen¹, Maria K Svensson², Ann Knight¹ and Johanna Dahlqvist³, ¹Uppsala University, Uppsala, Sweden, ²Uppsala University, Uppsala, ³Uppsala University Hospital, Uppsala, Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…
Abstract Number: 0522 • ACR Convergence 2025
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
Abdulrahman Y Almansouri¹, Jiayi Li², Ali Alhadri³, Keith Colaco⁴, Paula Harvey⁵, Shadi Ahktari⁶, Vinod Chandran⁷, Dafna D. Gladman⁸, Richard Cook² and Lihi Eder⁷, ¹King Faisal Specialist Hospital and Research Centre, University of Toronto and Women's College Hospital, Toronto, Canada, ²University of Waterloo, Waterloo, Canada, ³King Fahad Hospital, University of Toronto and Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of developing cardiovascular diseases, including arrhythmias. Given that traditional cardiovascular disease risk factors are prevalent…
Abstract Number: 0120 • ACR Convergence 2025
The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Emre Sahin¹, Maria Efthymiou², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Massimo Radin⁷, Jose Pardos-Gea⁸, MARIA ANGELES AGUIRRE ZAMORANO⁹, Nina Kello¹⁰, Diana Paredes-Ruiz¹¹, H Michael Belmont¹², Paul Fortin¹³, Denis WAHL¹⁴, Ware Branch¹⁵, Maria Gerosa¹⁶, Guilherme Ramires de Jesus¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsumi¹⁹, Giulia Pazzola²⁰, Laura Andreoli²¹, Ali Duarte-Garcia²², Esther Rodriguez-Almaraz²³, Michelle Petri²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Guillermo Pons-Estel²⁷, Hui Shi²⁸, Jason S. Knight²⁹, Rohan Willis³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University College London, London, United Kingdom, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Turin, Turin, Italy, ⁸Vall d’Hebron University Hospital, Barcelona, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹⁰Northwell Health, Brooklyn, NY, ¹¹Biobizkaia Health Research Institute, Barakaldo, Spain, ¹²NYU School of Medicine, New York, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁸Peking University First Hospital, Beijing, Beijing, China (People's Republic), ¹⁹Hokkaido University, Sapporo, Japan, ²⁰Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²¹University of Brescia, Brescia, Brescia, Italy, ²²Mayo Clinic, Rochester, MN, ²³Hospital Universitario ¹² de Octubre, Madrid, Spain, ²⁴Johns Hopkins University School of Medicine, Timonium, MD, ²⁵Hospital Clinic Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul, Istanbul, Turkey, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²⁸Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic), ²⁹University of Michigan, Ann Arbor, MI, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Although antiphospholipid antibodies (aPL) are well-established risk factors for thrombosis, heritable thrombophilias (HT) are also associated with venous thromboembolism (VTE). The latter includes deficiencies…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 2317 • ACR Convergence 2025
Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
Roel Sanchez Baez¹, Katherine Benson¹, Arthur Kavanaugh² and Monica Guma¹, ¹University of California, San Diego, La Jolla, CA, ²Division of Rheumatology, Autoimmunity and Inflammation, UC San Diego School of Medicine, La Jolla, CA
Background/Purpose: Patients with PsA have an elevated risk of cardiovascular (CV) disease. We assessed whether specific PsA features may predict CV events among PsA patients.Methods:…
Abstract Number: 1779 • ACR Convergence 2025
Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
Wenxian Zhou¹, Hannah Johnson², Michael Duryee², Engle Sharp², Carlos Hunter², Tate Johnson², Mabruka Alfaidi², Daniel Anderson³, Kishore Bidasee², Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ^30587964, Durham, NC
Background/Purpose: Endothelial cell (EC) dysfunction is a key driver of cardiovascular (CV) complications in rheumatoid arthritis (RA), yet mechanisms underlying EC dysfunction in RA are…
Abstract Number: 1427 • ACR Convergence 2025
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Ricardo I. De la Rosa-Vazquez⁵, Victoria P. Limas-Martínez⁵, Annette Dominguez-Guerra⁵, Jesus Alberto Cardenas-de la Garza⁶, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁷, Victor M Fraga-Enriquez⁸ and Diego Azamat Salcedo Almanza⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁸Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁹Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk due to a higher prevalence of comorbidities and chronic systemic inflammation. In those…
Abstract Number: 0709 • ACR Convergence 2025
Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Tracy Frech¹, Venkateswara Gogulamudi², Denisse Moreno², Eric Austin¹, Charles Frech³, Anna Hemnes¹, Tania Ruiz¹, Alex Shahin¹, Megha Talati¹, Colin Maguire⁴ and Anthony Donato², ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, ³Vanderbilt University, Nashville, TN, ⁴University of Utah, Salt Lake City, UT
Background/Purpose: Systemic sclerosis (SSc) disease models that faithfully recapitulate endothelial mediated vasculopathy are critical for testing and developing novel treatments. The generation of inducible pluripotential…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].